News
AEON
0.2538
+5.75%
0.0138
Weekly Report: what happened at AEON last week (1019-1023)?
Weekly Report · 1d ago
AEON Biopharma, Inc. Details ABP-450 Biosimilar Strategy and Plans Q4’26 IND Submission
NASDAQ · 3d ago
AEON Biopharma Posts Updated Investor Presentation Under Reg FD
TipRanks · 3d ago
Weekly Report: what happened at AEON last week (1012-1016)?
Weekly Report · 10/19 09:57
Weekly Report: what happened at AEON last week (1005-1009)?
Weekly Report · 10/12 10:00
Weekly Report: what happened at AEON last week (0928-1002)?
Weekly Report · 10/05 10:00
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/02 21:05
AEON Biopharma Consensus Price Target Raised by 16.39% to $1.81
NASDAQ · 10/02 13:06
Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 10/01 18:10
AEON Biopharma Is Maintained at Buy by Lake Street
Dow Jones · 10/01 16:19
Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2
Benzinga · 10/01 16:10
Aeon Biopharma price target raised to $2 from $1 at Lake Street
TipRanks · 10/01 12:46
Biotech Stocks Surge - NIVF +124%, CNTB +124%, SGMT +9%, VBIO +12%, AEON
NASDAQ · 09/30 18:49
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 09/30 17:06
Lake Street Remains a Buy on AEON Biopharma (AEON)
TipRanks · 09/30 13:16
AEON Gains FDA Feedback On ABP-450 Biosimilar Pathway
NASDAQ · 09/30 12:37
AEON Biopharma advances ABP-450 biosimilar development strategy
TipRanks · 09/30 12:34
AEON Clarifies ABP-450 Biosimilar Development Plan
NASDAQ · 09/30 12:30
Aeon FDA Type 2b meeting feedback clarifies development plan for ABP-450
TipRanks · 09/30 12:15
Weekly Report: what happened at AEON last week (0921-0925)?
Weekly Report · 09/28 09:56
More
Webull provides a variety of real-time AEON stock news. You can receive the latest news about Aeon Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About AEON
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.